Kessler Topaz Meltzer & Check, LLP said it is investigating potential federal securities law violations by Medline Inc. on behalf of investors in the company's Class A common stock after two sharp share-price declines tied to regulatory and earnings developments. A May 28, 2026 FDA warning letter, published on June 2, described "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" and said Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." Reuters reported on June 3, 2026 that the letter involved "violations of manufacturing quality standards," was the second such action against the company in two months, and cited failures to investigate microbial contamination incidents in finished drug products and inadequate cleaning practices. Medline shares fell over 7% after that news and dropped more than 12% again on August 5, 2026 after second-quarter results and lower full-year adjusted EBITDA guidance. The firm said investors who lost money may have legal rights under federal securities laws.